Coherus BioSciences Keeps Proving Wall Street Wrong
Coherus BioSciences (NASDAQ: CHRS) had the best-performing drug launch of 2019, doubled revenue in the first half of 2020 compared to the year-ago period, and turned 37% of total revenue into net income during the first six months of the year. Wall Street has responded with a yawn.
Shares of the biosimilar leader have gained only 4% since the beginning of the year. That matches the lowly performance of the S&P 500, which has faced significantly more uncertainty in the past seven-plus months. As a biosimilar developer, Coherus BioSciences faces limits on its near-term growth from its lone commercialized product, but it appears to be well positioned for success.
Here's what investors need to know about the latest operating results and the growth stock's puzzling trajectory.
Source Fool.com
